130
Participants
Start Date
October 28, 2014
Primary Completion Date
June 5, 2018
Study Completion Date
December 4, 2019
ASTX727 Dose Escalation
Oral investigational product and approved IV decitabine
ASTX727 Dose Confirmation
Randomization cross over design for courses 1 and 2
ASTX727 Fixed-Dose Combination
Fixed-dose investigational product
Weill Cornell Medical College - New York Presbyterian Hospital, New York
Roswell Park Cancer Institute, Buffalo
Johns Hopkins, Baltimore
Vanderbilt Ingram Cancer Center, Nashville
Horizon Oncology, Lafayette
Medical College of Wisconsin, Milwaukee
University of Chicago, Chicago
M. D. Anderson, Houston
Mayo Clinic, Phoenix
University of Southern California, Los Angeles
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
John Theurer Cancer Center/ Hackensack University Medical Center, Hackensack
University of Alberta Hospital, Edmonton
Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto
Princess Margaret Cancer Center, Toronto
Hôpital Maisonneuve-Rosemont, Montreal
Lead Sponsor
Astex Pharmaceuticals, Inc.
INDUSTRY